About Anthos Therapeutics
Anthos Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2019 by Paris Panayiotopoulos and Jonathan Freeman, and was acquired by Novartis in February 2025. Novel anticoagulants for thrombosis treatment are developed. It operates on a HealthTech model. Anthos Therapeutics has raised $250 million across 1 funding round from investors including Novartis, Blackstone and Novo Holdings. The company has 13 employees. Anthos Therapeutics was last valued at $3.1 billion in February 2025. Its chief executive, as recorded, is Bill Meury. Anthos Therapeutics offers products and services including Abelacimab. Its focus areas include Biotechnology and Anticoagulant Therapies. Its competitors include MacroGenics, Kodiak Sciences and Scholar Rock; 3 of its 3 listed competitors have raised funding.
Company details
Anthos Therapeutics is dedicated to addressing unmet medical needs in the field of anticoagulation. The company is engaged in the development of innovative therapies, particularly targeting Factor XI with their investigational drug Abelacimab. Their work is centered on areas such as atrial fibrillation and cancer-associated thrombosis, aiming to reduce the risk of bleeding compared to traditional treatments. Solutions are being developed to improve patient outcomes in cardiovascular and thrombotic conditions across global healthcare sectors.
- Headquarters Cambridge, United States
- Employees 13
- Founders Paris Panayiotopoulos, Jonathan Freeman
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website anthostherapeutics.com
- Social LinkedIn X
- Acquired by Novartis (Feb 2025)
Products & Services of Anthos Therapeutics
Anthos Therapeutics offers a comprehensive portfolio of products and services, including Abelacimab.
Abelacimab is developed as a novel anticoagulant therapy.
Funding Insights of Anthos Therapeutics
Anthos Therapeutics has successfully raised a total of $250M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $250 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $250M
- Total Rounds 1
- Last Round Private Equity Round — $250M
- First Round $250M
(Feb 2019)
- Investors Count 5
All 1 funding rounds of Anthos Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $250M | Private Equity Round | – | Blackstone, Novartis | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Anthos Therapeutics
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $3.1B (Feb 2025). 5 investors in total: 5 institutional.
Investors in Anthos Therapeutics
Anthos Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Blackstone and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Corporate backed venture capital firm investing in life sciences sector | nanfunglifesciences.com | San Francisco, United States | ||
A venture capital firm focused on life sciences innovation. | 2017 | pivotalbiovp.cn | Hong Kong, Hong Kong SAR | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark |
Investor details for Anthos Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Anthos Therapeutics
29 people are tracked at Anthos Therapeutics (16 in leadership, 6 in board & advisors, 7 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Paris Panayiotopoulos | Co-Founder | Leadership |
Jonathan Freeman | Co-Founder & COO | Leadership |
Bill Meury | CEO | Leadership |
Kate Li | Executive Director, Head Of Biostatistics & Data Analytics | Leadership |
Erica Bacsa | Executive Director, Clinical Operations | Leadership |
Nik Mehta | Chief Technical & Regulatory Officer | Leadership |
Dan Bloomfield | Chief Medical Officer | Leadership |
Doreen V. Morgan | Vice President Regulatory Affairs | Leadership |
Debra Freedholm | Sr Vp, Clinical Operations | Leadership |
Mike Doremus | Head, Technical Operations | Leadership |
Janeen Salter | Director, Clinical Operations | Leadership |
David McIntyre | Chief Financial Officer | Leadership |
Erika Dahl | Senior Director, Regulatory CMC | Leadership |
Bruce Hug | VP, Clinical Development | Leadership |
Mavis R. Moore | Director, Site Engagement | Leadership |
Gi Gi Galiano | Vice President, Program Management Office | Leadership |
Greg Norden | Director | Board & advisors |
Nicholas Galakatos | Director | Board & advisors |
Ari Brettman | Director | Board & advisors |
Richard C. Pasternak | Director | Board & advisors |
9 more people are available in the full profile.
Complete people profiles for Anthos Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Anthos Therapeutics
5 dated milestones of Anthos Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Anthos Therapeutics is founded.
- Funding First funding round of $250.0M.
- Milestone Reaches Unicorn status.
- Milestone Reaches Soonicorn status.
- Exit Acquired by Novartis.
Competitors of Anthos Therapeutics
Anthos Therapeutics has 3 listed competitors in our database, 3 of them funded. They include MacroGenics, Kodiak Sciences and Scholar Rock.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. | |
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. |
Detailed competitors of Anthos Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Anthos Therapeutics
The website of Anthos Therapeutics (anthostherapeutics.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▼ 2.2% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Anthos Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anthos Therapeutics
Complete news archive for Anthos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anthos Therapeutics
Anthos Therapeutics was founded in 2019.
Anthos Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Bill Meury is the CEO of Anthos Therapeutics, as recorded in our data.
Anthos Therapeutics is a funded company, having raised a total of $250M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $250M, raised on Feb 2019.
Anthos Therapeutics has 13 employees.
Anthos Therapeutics is dedicated to addressing unmet medical needs in the field of anticoagulation. The company is engaged in the development of innovative therapies, particularly targeting Factor XI with their investigational drug Abelacimab. Their work is centered on areas such as atrial fibrillation and cancer-associated thrombosis, aiming to reduce the risk of bleeding compared to traditional treatments. Solutions are being developed to improve patient outcomes in cardiovascular and thrombotic conditions across global healthcare sectors.
Anthos Therapeutics's top competitors include Kodiak Sciences, MacroGenics and Scholar Rock.
Anthos Therapeutics offers Abelacimab.
Anthos Therapeutics has 5 investors. Key investors include Novartis, Blackstone, Novo Holdings, Nan Fung Life Sciences, and Pivotal bioVenture Partners.
The valuation of Anthos Therapeutics is $3.1B as of Feb 2025.
Yes. Anthos Therapeutics was acquired by Novartis in February 2025.